Formation Bio is a U.S.-based technology and drug-development company, formerly known as TrialSpark, that uses AI and software to help pharmaceutical companies develop medicines more efficiently. It serves biopharmaceutical partners by supporting clinical-trial operations and other parts of the drug-development process.
Subscribe to see Formation Bio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Formation Bio is a biotech company headquartered in United States. Xcout tracks 12 named people at Formation Bio, including JeanYves Fromonot (Responsable pédagogique et développement Formateur en création d'activité). Xcout recorded 43 job postings from Formation Bio in the last 90 days, naming tools such as Claude Code, PyTorch, TensorFlow.
6 more named people on record for Formation Bio, with roles, board committees and tenure — see the full roster →
Xcout recorded 43 job postings from Formation Bio in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Formation Bio's hiring signals →
Based on 34 job postings in the last 8 weeks (10 Aug – 4 Oct 2026), compared with 158 scale-up healthcare companies.
This describes a hiring pattern — how often Formation Bio’s job postings ask for AI skills, and how that changed against the previous 8 weeks, ranked among its peers. It says nothing about the company’s products or performance.
Signed-in members see the AI-skill share and its change with peer percentiles, role mix, posting momentum and advertised US pay against the market.
A few of Formation Bio's closest competitors — see the full list of competitors and alternatives →
PhaseV uses causal machine learning and generative AI to optimize clinical trial designs and improve drug development processes.
Owkin builds artificial intelligence solutions to automate biopharmaceutical research and development and support clinical research. Its core product, K Pro, is an AI agent that analyzes multimodal patient data to generate insights, inform decision-making, and assist biopharma and healthcare professionals.
VeriSIM Life provides an AI-driven drug discovery and development platform called BIOiSIM that uses mechanistic and quantitative methods to predict patient outcomes and de-risk clinical trials. The company serves pharmaceutical companies, biotechnology firms, and academic research institutions by generating actionable insights for drug repurposing, safety-toxicity profiles, and efficacy predictions.
Bioneex provides an AI-powered biopharma matchmaking platform that connects early-stage drug development companies with strategic biopharma partners and venture capital investors. The platform facilitates licensing agreements, co-development partnerships, and investment opportunities for its users.
SwitchPoint Bio Holding, Inc. operates a platform that combines precision epigenomics and artificial intelligence to analyze cellular biology from blood samples. The company provides biomarker discovery, patient stratification, and treatment response mechanism readouts to support drug development and clinical research.
Prudentia Sciences is a technology company headquartered in Cambridge, Massachusetts. Launched with initial funding, the firm is dedicated to accelerating drug pipelines and transforming biopharmaceutical development.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.